Cargando…
Gut microbiota were altered with platelet count and red blood cell count in immune thrombocytopenia patients with different treatments
The gut microbiome is clearly linked to the development of various autoimmune diseases, however, its association with immune thrombocytopenia (ITP) is less well understood. The current study collected 73 samples, including 36 from healthy individuals and 37 from ITP patients. The gut microbial commu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225573/ https://www.ncbi.nlm.nih.gov/pubmed/37256109 http://dx.doi.org/10.3389/fcimb.2023.1168756 |
_version_ | 1785050403144990720 |
---|---|
author | Rui, Xue Fu, Yanjun Cai, Jie Zhang, Yu Fu, Qiang He, Chengtao |
author_facet | Rui, Xue Fu, Yanjun Cai, Jie Zhang, Yu Fu, Qiang He, Chengtao |
author_sort | Rui, Xue |
collection | PubMed |
description | The gut microbiome is clearly linked to the development of various autoimmune diseases, however, its association with immune thrombocytopenia (ITP) is less well understood. The current study collected 73 samples, including 36 from healthy individuals and 37 from ITP patients. The gut microbial community was assessed using 16s rRNA sequencing. Findings illustrated that the abundance of key microbiota was significantly higher in the ITP group. This group was further divided into three subgroups that received different treatments for ITP. A random forest model was used to predict the key microbiota and the identified bacteria were shown to easily distinguish between the healthy and the ITP treatment groups. Microbial function annotation and difference analysis showed that drug treatment changed the gut microbiota and may play a role in inducing host autoimmune responses by changing microbial metabolism pathways. Clinical indices also correlated negatively with changes in the microbiota after treatment. In summary, ITP patients who received drug treatment had significant differences in their microbiota along with a high abundance of bacteria. Thus, the microbiome could be used as a biomarker to distinguish between healthy and ITB groups. The key differential bacteria could help to regulate the number of platelets in ITP patients and provide a red blood cell overstock. |
format | Online Article Text |
id | pubmed-10225573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102255732023-05-30 Gut microbiota were altered with platelet count and red blood cell count in immune thrombocytopenia patients with different treatments Rui, Xue Fu, Yanjun Cai, Jie Zhang, Yu Fu, Qiang He, Chengtao Front Cell Infect Microbiol Cellular and Infection Microbiology The gut microbiome is clearly linked to the development of various autoimmune diseases, however, its association with immune thrombocytopenia (ITP) is less well understood. The current study collected 73 samples, including 36 from healthy individuals and 37 from ITP patients. The gut microbial community was assessed using 16s rRNA sequencing. Findings illustrated that the abundance of key microbiota was significantly higher in the ITP group. This group was further divided into three subgroups that received different treatments for ITP. A random forest model was used to predict the key microbiota and the identified bacteria were shown to easily distinguish between the healthy and the ITP treatment groups. Microbial function annotation and difference analysis showed that drug treatment changed the gut microbiota and may play a role in inducing host autoimmune responses by changing microbial metabolism pathways. Clinical indices also correlated negatively with changes in the microbiota after treatment. In summary, ITP patients who received drug treatment had significant differences in their microbiota along with a high abundance of bacteria. Thus, the microbiome could be used as a biomarker to distinguish between healthy and ITB groups. The key differential bacteria could help to regulate the number of platelets in ITP patients and provide a red blood cell overstock. Frontiers Media S.A. 2023-05-15 /pmc/articles/PMC10225573/ /pubmed/37256109 http://dx.doi.org/10.3389/fcimb.2023.1168756 Text en Copyright © 2023 Rui, Fu, Cai, Zhang, Fu and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Rui, Xue Fu, Yanjun Cai, Jie Zhang, Yu Fu, Qiang He, Chengtao Gut microbiota were altered with platelet count and red blood cell count in immune thrombocytopenia patients with different treatments |
title | Gut microbiota were altered with platelet count and red blood cell count in immune thrombocytopenia patients with different treatments |
title_full | Gut microbiota were altered with platelet count and red blood cell count in immune thrombocytopenia patients with different treatments |
title_fullStr | Gut microbiota were altered with platelet count and red blood cell count in immune thrombocytopenia patients with different treatments |
title_full_unstemmed | Gut microbiota were altered with platelet count and red blood cell count in immune thrombocytopenia patients with different treatments |
title_short | Gut microbiota were altered with platelet count and red blood cell count in immune thrombocytopenia patients with different treatments |
title_sort | gut microbiota were altered with platelet count and red blood cell count in immune thrombocytopenia patients with different treatments |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225573/ https://www.ncbi.nlm.nih.gov/pubmed/37256109 http://dx.doi.org/10.3389/fcimb.2023.1168756 |
work_keys_str_mv | AT ruixue gutmicrobiotawerealteredwithplateletcountandredbloodcellcountinimmunethrombocytopeniapatientswithdifferenttreatments AT fuyanjun gutmicrobiotawerealteredwithplateletcountandredbloodcellcountinimmunethrombocytopeniapatientswithdifferenttreatments AT caijie gutmicrobiotawerealteredwithplateletcountandredbloodcellcountinimmunethrombocytopeniapatientswithdifferenttreatments AT zhangyu gutmicrobiotawerealteredwithplateletcountandredbloodcellcountinimmunethrombocytopeniapatientswithdifferenttreatments AT fuqiang gutmicrobiotawerealteredwithplateletcountandredbloodcellcountinimmunethrombocytopeniapatientswithdifferenttreatments AT hechengtao gutmicrobiotawerealteredwithplateletcountandredbloodcellcountinimmunethrombocytopeniapatientswithdifferenttreatments |